GlassScriptPhysician profile
Pallav Mehta
NPI 1720126170
$21,656.68
in general payments reported to CMS, 2019-2025
6 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,563 · 2021: $262 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116 · Education: $72.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.98 |
| Education | $72.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,005.50 | 2019-2020 | |
| Pfizer INC. | $6,800.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $5,650.55 | 2019 | |
| Fresenius Kabi USA, LLC | $115.98 | 2025 | |
| Seagen INC. | $72.73 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pallav Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.